A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens

A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens

With the development of more effective direct-acting antivirals (DAAs), dual- or triple-therapy regimens represent the major strategy used to cure chronic hepatitis C virus (HCV) infection. Thus, shorter treatment duration regimens with low burden, few adverse effects and good patient adherence are...

Full description

Bibliographic Details
Main Authors: Hu Li, Jia-Li Tan, Jian-Rui Li, Nan-Nan Liu, Jin-Hua Chen, Xiao-Qin Lv, Li-li Zou, Biao Dong, Zong-Gen Peng, Jian-Dong Jiang
Format: Article
Language:English
Published: Elsevier 2019-08-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Hepatitis C virus
HCV-positive hepatocytes
DAA treatment regimens
Shorter therapy duration
Virologic relapse
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332219309564

Internet

http://www.sciencedirect.com/science/article/pii/S0753332219309564

Similar Items